Based on our work, it would be interesting in the future to design clinical trials involving combination chemoradiotherapy/anti‐FGF2 agents for the treatment of advanced CSCC in patients with high LNMAC expression. This evidence concerns the gene FGF2 and skin squamous cell carcinoma.